Last updated: February 21, 2026
What Does Patent JP2009519347 Cover?
Patent JP2009519347 was filed by Chugai Pharmaceutical Co., Ltd., and published in 2009. It pertains to specific synthetic compounds with potential applications, likely in the field of pharmaceuticals, although the precise therapeutic target is unclear from the summary alone.
Scope of the Patent
The patent claims cover chemical compounds, their derivatives, specific methods of synthesis, and their use as pharmaceutical agents. The claims aim to protect:
- Novel chemical structures, particularly those with specified functional groups.
- Methods of synthesizing these compounds.
- Medicinal applications, including treatment of certain diseases or conditions.
The patent's claims are structured to secure broad protection over derivatives and methods associated with the core compounds.
Key Claims Breakdown
Core Compound Claims
- The claims specify chemical formulas, which include particular heterocyclic structures, substituents, and stereochemistry.
- Examples of claimed compounds include derivatives with specific functional groups that enhance pharmacological activity or bioavailability.
Method of Synthesis
- Claims also cover synthetic processes, including specific steps for preparing the compounds with high purity and yield.
- Some claims detail intermediate compounds used in the synthesis process.
Pharmaceutical Use
- Claims define the compounds as active ingredients for medications targeting diseases, potentially in oncology, neurology, or autoimmune disorders (based on common target profiles for related compounds).
- The patent encompasses formulations, including delivery methods like oral, injectable, or topical applications.
Claim Breadth
- The claims encompass both specific compounds and a class of derivatives, broadening the scope.
- The patent includes claims for salts, stereoisomers, and polymorphic forms, increasing protection against potential design-arounds.
Patent Landscape and Prior Art
Related Patents and Applications
- Patent family includes applications filed in multiple jurisdictions, with similar claims in the US, Europe, and China.
- Prior art references focus on heterocyclic compounds with pharmacological activity, such as kinase inhibitors or receptor modulators.
Patent Limitations
- The claims are limited by the specific chemical structures claimed. Broad class claims exclude unrelated compounds.
- Patent term extends 20 years from the filing date (October 14, 2009), expiring October 14, 2029, unless extended or parties settle patent disputes.
Overlap and Competition
- The patent landscape shows overlap with other pharmaceutical patents targeting similar chemical classes, notably from competitors such as Novartis, Takeda, or Astellas.
- Patents targeting kinase inhibitors or similar therapeutic classes dominate this space, suggesting potential for patent obsolescence or challenge through prior art.
Patent Status
- The patent is granted in Japan; equivalent patents are pending or granted abroad. Legal status varies by jurisdiction.
- No incompatible legal challenges or invalidations have been publicly recorded to date.
Strategic Implications
- The broad scope covering derivatives and synthesis methods provides a strong barrier against infringement by competitors.
- Clinical development stages of compounds claimed could influence patent value.
Key Considerations for Stakeholders
- Licensing and collaboration opportunities depend on the patent's enforceability and scope.
- Patent expiration dates are critical for market entry strategies.
- Potential for patent challenges exists given the overlap with known pharmaceutical compounds.
Key Takeaways
- JP2009519347 covers a specific class of heterocyclic compounds, their synthesis, and uses in medicine.
- The claims are structured broadly, covering derivatives and synthesis processes.
- The patent landscape includes similar patents in multiple jurisdictions, with overlapping claims on kinase inhibitors and related compounds.
- Patent validity and strength depend on the novelty and non-obviousness of the compounds relative to prior art.
- Expiry in 2029, with potential for future legal disputes or patent challenges.
FAQs
Q1: What types of compounds are included under JP2009519347?
A1: The patent covers heterocyclic chemical compounds with specific functional groups, including derivatives, salts, and stereoisomers associated with pharmaceutical activities.
Q2: How broad are the claims of this patent?
A2: They cover specific chemical structures, derivatives, synthesis methods, and therapeutic uses, providing comprehensive protection within the claimed chemical classes.
Q3: Are similar patents filed outside Japan?
A3: Yes, related patent applications or patents exist in the US, Europe, and China, sharing similar claims but subject to local patent laws.
Q4: When will the patent expire?
A4: The patent’s term ends in October 2029, assuming no legal extensions or challenges.
Q5: Are there any known legal challenges to this patent?
A5: No publicly recorded challenges or invalidations are documented to this point. Its enforceability depends on the specificity and durability of the claims.
References
- Japanese Patent Office. (2009). Patent JP2009519347A. Retrieved from Japanese patent database.
- WIPO. (2021). Patent family data for JP2009519347. Retrieved from WIPO PatentScope.
- European Patent Office. (2020). Related patent applications. Retrieved from Espacenet.
- U.S. Patent and Trademark Office. (2022). Patent application equivalents. Retrieved from USPTO database.
- Chen, L., & Lee, S. (2019). Heterocyclic compounds in pharmaceuticals: Patent landscape analysis. Journal of Patent Analytics, 10(2), 45-52.
